Madrigal Pharmaceuticals (YDO1) Stock Statistics & Valuation Metrics

Madrigal Pharmaceuticals has a market cap or net worth of CHF9.57B. The enterprise value is CHF15.16K.

Madrigal Pharmaceuticals has ― shares outstanding. The number of shares has decreased by -2.65% in one year.

Madrigal Pharmaceuticals’s return on equity (ROE) is -0.48 and return on invested capital (ROIC) is -31.58%.

The current PE Ratio of Madrigal Pharmaceuticals is ―. Madrigal Pharmaceuticals’s PEG ratio is 1.10.

In the last 12 months, Madrigal Pharmaceuticals had revenue of 958.40M and earned -288.28M in profits. Earnings per share was -12.85.

In the last 12 months, operating cash flow was -197.72M and capital expenditures -8.57M, giving a free cash flow of -206.28M billion.

Madrigal Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Madrigal Pharmaceuticals upcoming earnings date is Oct 29, 2026, Before Open (Confirmed).

Madrigal Pharmaceuticals as a current ratio of 4.01, with Debt / Equity ratio of 66.40%

In the past 12 months, Madrigal Pharmaceuticals has paid 0.00 in taxes.

Madrigal Pharmaceuticals EV to EBITDA ratio is -49.99, with an EV/FCF ratio of -69.57.

Madrigal Pharmaceuticals has CHF838.75M in cash and marketable securities with CHF347.75M in debt, giving a net cash position of CHF491.00M billion.

Gross margin is 91.48%, with operating margin of -31.31%, and net profit margin of -30.08%.

The average price target for Madrigal Pharmaceuticals is CHF559.42, which is 11.43% higher than the current price. The consensus rating is Strong Buy